NCT04208347 2026-01-23
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
Ruijin Hospital
Phase 2/3 Active not recruiting
Clinical Trials
9 trialsNCT07309419 2025-12-30
Cocktail-001
Shanghai Zhongshan Hospital
Phase 2/3 Not yet recruiting
NCT04521153 2025-05-11
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT06288373 2024-10-30
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Phase 2/3 Recruiting
NCT05062837 2024-01-23
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Guangxi Medical University
Phase 2/3 Unknown
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT04803539 2023-02-21
Artemis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3 Recruiting
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT04510610 2020-08-12
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2/3 Unknown